Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10
Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Incyte Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 13
Private Equity 14
TRC Capital to Acquire Incyte in Tender Offer for USD133.32 Million 14
Partnerships 15
Incyte and Foundation Medicine Enter into Agreement 15
Immunovaccine Enters into Agreement with Incyte 16
Incyte and Syros Pharma Enter into Agreement 17
AstraZeneca and MedImmune Expands Agreement with Incyte 18
Bristol-Myers Squibb and Incyte Enter into Agreement 19
Incyte Enters into Research Agreement with Abramson Cancer Center 20
Incyte Enters into Distribution Agreement with GENESIS Pharma 21
Incyte Enters into Agreement with Moffitt Cancer Center 22
Incyte Enters into Agreement with AstraZeneca 23
Incyte Extends Partnership with Merck 24
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 25
Licensing Agreements 26
Incyte Enters into Licensing Agreement with MacroGenics 26
Incyte Enters into Licensing Agreement with Calithera Biosciences 27
Incyte Enters into Licensing Agreement with Merus 29
Incyte Amends Licensing Agreement with ARIAD Pharma 31
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 32
Incyte Amends Licensing Agreement with Agenus 33
Equity Offering 35
Syros Pharma Raises USD1.2 Million in Private Placement of Shares 35
Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 36
Incyte Raises USD650 Million in Public Offering of Shares 37
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 38
Agenus Raises USD35 Million in Private Placement of Common Stock 40
Debt Offering 41
Incyte Completes Private Placement Of Notes Due 2018 For US$375 Million 41
Incyte Completes Private Placement Of Notes Due 2020 For US$375 Million 43
Acquisition 45
Gilead Sciences May Acquire Incyte 45
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 46
Incyte Corp – Key Competitors 48
Incyte Corp – Key Employees 49
Incyte Corp – Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 51
Financial Announcements 51
Sep 30, 2018: Incyte reports 2018 third quarter and nine month financial results and provides updates on key clinical programs 51
Jul 31, 2018: Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs 57
May 01, 2018: Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs 60
Feb 15, 2018: Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs 63
Oct 31, 2017: Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs 66
May 04, 2017: Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs 68
Feb 14, 2017: Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs 70
Corporate Communications 73
Sep 06, 2018: Incyte announces Chief Financial Officer David Gryska to retire at the End of 2018 73
Oct 30, 2017: Incyte Names New Member to Its Board of Directors 74
Oct 06, 2017: Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware 75
Product News 76
06/21/2018: Incyte to Present Data on INCB54828 at 2018 Investor and Analyst Event 76
04/20/2017: Incyte Presents Data on INCB050465 At at the 2017 ASCO Annual Meeting 77
03/07/2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 78
03/07/2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 79
Clinical Trials 80
Nov 10, 2017: MacroGenics Announces Poster Presentations on MGA012 at 32nd Annual SITC Meeting 2017 80
Oct 19, 2017: Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda 81
Jun 05, 2017: CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting 82
Apr 20, 2017: Incyte Presents Data on CB-1158 at the 2017 ASCO Annual Meeting 83
Mar 28, 2017: Calithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85
Incyte Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Incyte Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10
Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 13
TRC Capital to Acquire Incyte in Tender Offer for USD133.32 Million 14
Incyte and Foundation Medicine Enter into Agreement 15
Immunovaccine Enters into Agreement with Incyte 16
Incyte and Syros Pharma Enter into Agreement 17
AstraZeneca and MedImmune Expands Agreement with Incyte 18
Bristol-Myers Squibb and Incyte Enter into Agreement 19
Incyte Enters into Research Agreement with Abramson Cancer Center 20
Incyte Enters into Distribution Agreement with GENESIS Pharma 21
Incyte Enters into Agreement with Moffitt Cancer Center 22
Incyte Enters into Agreement with AstraZeneca 23
Incyte Extends Partnership with Merck 24
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 25
Incyte Enters into Licensing Agreement with MacroGenics 26
Incyte Enters into Licensing Agreement with Calithera Biosciences 27
Incyte Enters into Licensing Agreement with Merus 29
Incyte Amends Licensing Agreement with ARIAD Pharma 31
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 32
Incyte Amends Licensing Agreement with Agenus 33
Syros Pharma Raises USD1.2 Million in Private Placement of Shares 35
Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 36
Incyte Raises USD650 Million in Public Offering of Shares 37
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 38
Agenus Raises USD35 Million in Private Placement of Common Stock 40
Incyte Completes Private Placement Of Notes Due 2018 For US$375 Million 41
Incyte Completes Private Placement Of Notes Due 2020 For US$375 Million 43
Gilead Sciences May Acquire Incyte 45
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 46
Incyte Corp, Key Competitors 48
Incyte Corp, Key Employees 49
Incyte Corp, Subsidiaries 50
List of Figures
Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10